Podcasts about turing pharmaceuticals

La industria farmacéutica desempeña un papel crucial en la sociedad al proporcionar medicamentos y tratamientos que mejoran y salvan vidas. Sin embargo, como en cualquier industria, también ha sido escenario de casos de fraude, estafas y mala praxis. Estos incidentes no solo erosionan la confianza del público en la industria, sino que también plantean cuestionamientos éticos sobre la priorización de las ganancias por encima de la salud y el bienestar de los pacientes. En este artículo, exploraremos algunos ejemplos notorios de fraudes, estafas y mala praxis en la industria farmacéutica, así como las implicaciones y las medidas tomadas para abordar estos problemas. Casos Emblemáticos de Fraude y Estafas Caso Turing Pharmaceuticals y el aumento de precios de Daraprim: En 2015, Turing Pharmaceuticals, dirigida por Martin Shkreli, adquirió los derechos del medicamento Daraprim, utilizado en el tratamiento de infecciones parasitarias. La compañía aumentó drásticamente el precio del medicamento en un 5,000%, lo que generó indignación pública y puso de relieve las prácticas de fijación de precios abusivas en la industria. Caso Insys Therapeutics y el opioidi OxyContin: Insys Therapeutics promovió de manera agresiva su fentanilo de acción rápida, Subsys, para el tratamiento del dolor, incluso cuando no estaba indicado. La compañía se enfrentó a acusaciones de sobornar a médicos para recetar el medicamento y participar en tácticas de marketing engañosas, lo que contribuyó a la crisis de opioides en Estados Unidos. Caso GlaxoSmithKline y el escándalo del Paxil: La compañía farmacéutica GlaxoSmithKline fue acusada de ocultar datos sobre la seguridad y eficacia del antidepresivo Paxil en pacientes jóvenes. También se reveló que GSK había sobornado a médicos y manipulado la información en beneficio propio. Casos de Mala Praxis y Fallos en la Investigación Retiro de medicamentos después de la aprobación: En ocasiones, medicamentos que han sido aprobados por las agencias reguladoras se retiran del mercado debido a problemas de seguridad que no se identificaron durante los ensayos clínicos. Ejemplos notables incluyen el retiro del medicamento Vioxx de Merck por aumentar el riesgo de ataques cardíacos y accidentes cerebrovasculares. Estudios clínicos sesgados: Se han documentado casos en los que los resultados de estudios clínicos son manipulados o sesgados para favorecer los intereses de la empresa farmacéutica patrocinadora. Esto puede llevar a la aprobación de medicamentos que en realidad no son tan seguros o efectivos como se afirma. Implicaciones y Medidas Correctivas Los casos de fraude, estafas y mala praxis en la industria farmacéutica tienen implicaciones graves para la salud pública y la confianza en el sistema de atención médica. Para abordar estos problemas, se han tomado y se siguen tomando diversas medidas: Mayor transparencia: Las agencias reguladoras y las empresas farmacéuticas están bajo presión para aumentar la transparencia en la divulgación de datos de ensayos clínicos y en la presentación de informes sobre la seguridad y eficacia de los medicamentos. Regulaciones más estrictas: Se están implementando regulaciones más estrictas para prevenir la fijación de precios abusivos y para garantizar que los medicamentos se receten de manera adecuada y segura. Control de conflictos de interés: Se están adoptando medidas para controlar los conflictos de interés en la relación entre médicos y la industria farmacéutica, como la divulgación pública de las relaciones financieras. Mayor supervisión y sanciones: Las empresas y personas involucradas en prácticas fraudulentas o de mala praxis están siendo investigadas y, en algunos casos, enfrentan sanciones legales y multas significativas. Conclusión Si bien la mayoría de las empresas farmacéuticas están comprometidas con el desarrollo y la comercialización de tratamientos que mejoran la salud humana, los casos de fraude, estafas y mala praxis han sacudido la confianza del público en la industria. Es esencial continuar trabajando en la implementación de regulaciones más estrictas, la promoción de la transparencia y la ética, y la vigilancia constante para garantizar que los pacientes reciban medicamentos seguros y efectivos sin que se comprometa su bienestar en aras de las ganancias. ---------------------------------------------------------------------------------------------------------------- Antena Historia te regala 30 días PREMIUM, para que lo disfrutes https://www.ivoox.com/premium?affiliate-code=b4688a50868967db9ca413741a54cea5 ---------------------------------------------------------------------------------------- Produce Antonio Cruz Edita ANTENA HISTORIA Antena Historia (podcast) forma parte del sello iVoox Originals ---------------------------------------------------------------------------------------- web……….https://antenahistoria.com/ correo.....info@antenahistoria.com Facebook…..Antena Historia Podcast | Facebook Twitter…...https://twitter.com/AntenaHistoria Telegram…...https://t.me/foroantenahistoria DONACIONES PAYPAL...... https://paypal.me/ancrume ---------------------------------------------------------------------------------------- ¿QUIERES ANUNCIARTE en ANTENA HISTORIA?, menciones, cuñas publicitarias, programas personalizados, etc. Dirígete a Antena Historia - AdVoices Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

La industria farmacéutica desempeña un papel crucial en la sociedad al proporcionar medicamentos y tratamientos que mejoran y salvan vidas. Sin embargo, como en cualquier industria, también ha sido escenario de casos de fraude, estafas y mala praxis. Estos incidentes no solo erosionan la confianza del público en la industria, sino que también plantean cuestionamientos éticos sobre la priorización de las ganancias por encima de la salud y el bienestar de los pacientes. En este artículo, exploraremos algunos ejemplos notorios de fraudes, estafas y mala praxis en la industria farmacéutica, así como las implicaciones y las medidas tomadas para abordar estos problemas. Casos Emblemáticos de Fraude y Estafas Caso Turing Pharmaceuticals y el aumento de precios de Daraprim: En 2015, Turing Pharmaceuticals, dirigida por Martin Shkreli, adquirió los derechos del medicamento Daraprim, utilizado en el tratamiento de infecciones parasitarias. La compañía aumentó drásticamente el precio del medicamento en un 5,000%, lo que generó indignación pública y puso de relieve las prácticas de fijación de precios abusivas en la industria. Caso Insys Therapeutics y el opioidi OxyContin: Insys Therapeutics promovió de manera agresiva su fentanilo de acción rápida, Subsys, para el tratamiento del dolor, incluso cuando no estaba indicado. La compañía se enfrentó a acusaciones de sobornar a médicos para recetar el medicamento y participar en tácticas de marketing engañosas, lo que contribuyó a la crisis de opioides en Estados Unidos. Caso GlaxoSmithKline y el escándalo del Paxil: La compañía farmacéutica GlaxoSmithKline fue acusada de ocultar datos sobre la seguridad y eficacia del antidepresivo Paxil en pacientes jóvenes. También se reveló que GSK había sobornado a médicos y manipulado la información en beneficio propio. Casos de Mala Praxis y Fallos en la Investigación Retiro de medicamentos después de la aprobación: En ocasiones, medicamentos que han sido aprobados por las agencias reguladoras se retiran del mercado debido a problemas de seguridad que no se identificaron durante los ensayos clínicos. Ejemplos notables incluyen el retiro del medicamento Vioxx de Merck por aumentar el riesgo de ataques cardíacos y accidentes cerebrovasculares. Estudios clínicos sesgados: Se han documentado casos en los que los resultados de estudios clínicos son manipulados o sesgados para favorecer los intereses de la empresa farmacéutica patrocinadora. Esto puede llevar a la aprobación de medicamentos que en realidad no son tan seguros o efectivos como se afirma. Implicaciones y Medidas Correctivas Los casos de fraude, estafas y mala praxis en la industria farmacéutica tienen implicaciones graves para la salud pública y la confianza en el sistema de atención médica. Para abordar estos problemas, se han tomado y se siguen tomando diversas medidas: Mayor transparencia: Las agencias reguladoras y las empresas farmacéuticas están bajo presión para aumentar la transparencia en la divulgación de datos de ensayos clínicos y en la presentación de informes sobre la seguridad y eficacia de los medicamentos. Regulaciones más estrictas: Se están implementando regulaciones más estrictas para prevenir la fijación de precios abusivos y para garantizar que los medicamentos se receten de manera adecuada y segura. Control de conflictos de interés: Se están adoptando medidas para controlar los conflictos de interés en la relación entre médicos y la industria farmacéutica, como la divulgación pública de las relaciones financieras. Mayor supervisión y sanciones: Las empresas y personas involucradas en prácticas fraudulentas o de mala praxis están siendo investigadas y, en algunos casos, enfrentan sanciones legales y multas significativas. Conclusión Si bien la mayoría de las empresas farmacéuticas están comprometidas con el desarrollo y la comercialización de tratamientos que mejoran la salud humana, los casos de fraude, estafas y mala praxis han sacudido la confianza del público en la industria. Es esencial continuar trabajando en la implementación de regulaciones más estrictas, la promoción de la transparencia y la ética, y la vigilancia constante para garantizar que los pacientes reciban medicamentos seguros y efectivos sin que se comprometa su bienestar en aras de las ganancias. ---------------------------------------------------------------------------------------------------------------- Antena Historia te regala 30 días PREMIUM, para que lo disfrutes https://www.ivoox.com/premium?affiliate-code=b4688a50868967db9ca413741a54cea5 ---------------------------------------------------------------------------------------- Produce Antonio Cruz Edita ANTENA HISTORIA Antena Historia (podcast) forma parte del sello iVoox Originals ---------------------------------------------------------------------------------------- web……….https://antenahistoria.com/ correo.....info@antenahistoria.com Facebook…..Antena Historia Podcast | Facebook Twitter…...https://twitter.com/AntenaHistoria Telegram…...https://t.me/foroantenahistoria DONACIONES PAYPAL...... https://paypal.me/ancrume ---------------------------------------------------------------------------------------- ¿QUIERES ANUNCIARTE en ANTENA HISTORIA?, menciones, cuñas publicitarias, programas personalizados, etc. Dirígete a Antena Historia - AdVoices Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

The high cost of prescription drugs affects us all. But what's behind them? Is it just pharmaceutical company greed?Welcome to Lean to the Left, the podcast that explores important developments that shape our society and our world. Our guest today is Hank Laskey, PhD, a longtime adviser and consultant in the pharmaceutical industry.Hank brings a ton of knowledge and perspective about this industry and the companies that provide the life-saving drugs so important to us all. We'll tackle some of the factors that affect the prices we all pay for our prescriptions and hear his thoughts about what can, and should, be done about that.Dr. Laskey also will share with us insight that will help those who want to enter that industry, or advance within in it. That's part of the reason why he authored a book called “The Global Pharmaceutical Industry: Economic Structure, Government Regulation, and History.”The book combines the study of business and economics with medicine, science, and technology-all within a regulatory framework-and helps the reader understand the multifaceted global pharmaceutical industry.Dr. Laskey, welcome to the Lean to the Left podcast.Q. One of the major concerns that most of us have today is the high cost of prescription drugs. With insulin, for example, it got to the point where Congress capped the price at $35 per month—but only for Medicare patients. Can you walk us through what's involved here?Q. What did you think of Martin Shkreli, the Turing Pharmaceuticals owner who jacked up the price of insulin to crazy levels and who raised the cost of a decades-old drug used to treat infections in babies and people with AIDS by more than 5,000 percent?Q. Every time we turn on the TV we're bombarded with ads for pharmaceutical products for everything from HIV to cancer to skin rashes. These products are targeted to narrow segments of the population who suffer from these various diseases. Yet, those ads are within programming that is geared to a general audience. Does this make sense?Q. How does the marketing side of the industry interact with the medical side? Are these marketing costs reflected in the ultimate price consumers must pay for these drugs?Q. PhRMA, the lobbying organization representing the industry, has published a piece on the web that claims that “due to negotiations in the market,” prices health plans paid for brand medicines increased by just 1 percent on average in 2021. They blame insurers and other middlemen for forcing many of the sickest patients to pay high out-of-pocket costs. Really? Your comment?Q. Sometimes at the end of a commercial, after all of the possible side effects are revealed, the voice/over will say that “X company may be able to help” with the cost. What are these patient assistance programs offered by biopharmaceutical companies and how do they work?Q. What are the differences between generic drugs and brand medicines? Are the generics just as good and as effective?Q. The industry always claims that the cost for prescription drugs must reflect the high cost of research and development. To many, this seems like a cop-out. Your thoughts?Q. What's your view of federal regulation of the industry? Does there need to be more? In what areas?Q. Let's talk about those individuals who would like a career in this industry. You've worked as a consultant, published research articles, taught courses for several leading industry companies. What's your advice to those who want a career in the pharmaceutical industry or move up within it? Does your book address this?Q. Where can people find your book?Become a supporter of this podcast: https://www.spreaker.com/podcast/the-lean-to-the-left-podcast--4719048/support.

The high cost of prescription drugs affects us all. But what's behind them? Is it just pharmaceutical company greed?Welcome to Lean to the Left, the podcast that explores important developments that shape our society and our world. Our guest today is Hank Laskey, PhD, a longtime adviser and consultant in the pharmaceutical industry.Hank brings a ton of knowledge and perspective about this industry and the companies that provide the life-saving drugs so important to us all. We'll tackle some of the factors that affect the prices we all pay for our prescriptions and hear his thoughts about what can, and should, be done about that.Dr. Laskey also will share with us insight that will help those who want to enter that industry, or advance within in it. That's part of the reason why he authored a book called “The Global Pharmaceutical Industry: Economic Structure, Government Regulation, and History.”The book combines the study of business and economics with medicine, science, and technology-all within a regulatory framework-and helps the reader understand the multifaceted global pharmaceutical industry.Dr. Laskey, welcome to the Lean to the Left podcast.Q. One of the major concerns that most of us have today is the high cost of prescription drugs. With insulin, for example, it got to the point where Congress capped the price at $35 per month—but only for Medicare patients. Can you walk us through what's involved here?Q. What did you think of Martin Shkreli, the Turing Pharmaceuticals owner who jacked up the price of insulin to crazy levels and who raised the cost of a decades-old drug used to treat infections in babies and people with AIDS by more than 5,000 percent?Q. Every time we turn on the TV we're bombarded with ads for pharmaceutical products for everything from HIV to cancer to skin rashes. These products are targeted to narrow segments of the population who suffer from these various diseases. Yet, those ads are within programming that is geared to a general audience. Does this make sense?Q. How does the marketing side of the industry interact with the medical side? Are these marketing costs reflected in the ultimate price consumers must pay for these drugs?Q. PhRMA, the lobbying organization representing the industry, has published a piece on the web that claims that “due to negotiations in the market,” prices health plans paid for brand medicines increased by just 1 percent on average in 2021. They blame insurers and other middlemen for forcing many of the sickest patients to pay high out-of-pocket costs. Really? Your comment?Q. Sometimes at the end of a commercial, after all of the possible side effects are revealed, the voice/over will say that “X company may be able to help” with the cost. What are these patient assistance programs offered by biopharmaceutical companies and how do they work?Q. What are the differences between generic drugs and brand medicines? Are the generics just as good and as effective?Q. The industry always claims that the cost for prescription drugs must reflect the high cost of research and development. To many, this seems like a cop-out. Your thoughts?Q. What's your view of federal regulation of the industry? Does there need to be more? In what areas?Q. Let's talk about those individuals who would like a career in this industry. You've worked as a consultant, published research articles, taught courses for several leading industry companies. What's your advice to those who want a career in the pharmaceutical industry or move up within it? Does your book address this?Q. Where can people find your book?This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/4719048/advertisement

By his early 30s, Martin Shkreli had held a variety of impressive roles; he was the co-founder of multiple successful hedge funds, CEO of biotechnology firm Retrophin; and founder and CEO of Turing Pharmaceuticals. So, how did young Martin Shkreli, with no formal training in chemistry and a Bachelor's Degree in business administration, become a pharmaceutical CEO and have an estimated worth by Fortune magazine in 2016 of $45 million? And how did Martin Shkreli only a few years later become a convicted felon worth practically nothing; referred to by the media as "Pharma Bro" and "the most hated man in America"? And whatever happened to that unreleased Wu Tang Clan Album Martin Shkreli bought for $2 million? Find out today on the Controversial Figures Podcast.Connect with us on Twitter: https://twitter.com/FiguresPodcastEpisode Sources:CNBC https://www.cnbc.com/2019/08/07/retrophin-paid-martin-shkreli-to-settle-all-legal-claims.htmlNetFlix Dirty Money, Drug Short episodeVanity Fair https://www.vanityfair.com/news/2015/12/martin-shkreli-pharmaceuticals-ceo-interviewWikipediaMartin Shkreli https://en.wikipedia.org/wiki/Martin_ShkreliNaked Short Sell https://en.wikipedia.org/wiki/Naked_short_sellingOnce Upon a Time in Shaolin https://en.wikipedia.org/wiki/Once_Upon_a_Time_in_ShaolinXconomy https://xconomy.com/san-diego/2019/08/22/retrophin-sinks-as-drug-pharma-bro-martin-shkreli-co-invented-fails/ Music: The 6 is Silent by SkyjellyBuzzsprout - Let's get your podcast launched! Start for FREEDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show (https://www.patreon.com/controversialfigurespod)

HAPPY NEW YEAR A Decade Marked By Outrage Over Drug Prices Martin Shkreli, the former CEO of Turing Pharmaceuticals, who was called before Cummings' committee in2016. After hiking the price of an old drug for parasitic infections to $750 a pill from $13.50, Shkreli became the poster boy for pharmaceutical greed that helped define the past decade. Meanwhile, nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Of relevance, perhaps to our NA members, Daraprim: An old drug gets a huge new price For decades, Daraprim has been the go-to medicine for treating toxoplasmosis, a parasitic infection especially dangerous for people with compromised immune systems, such as people living with HIV and patients who've undergone organ transplants. The drug was approved by the Food and Drug Administration in 1953, and its patents expired long ago. But there wasn't a generic version available, and there was only one supplier in the United States. Even so, Daraprim cost just $13.50 a pill in early 2015. Then Turing Pharmaceuticals bought the rights to the drug and raised its list price more than 5,000% overnight. Another company called Valeant did the same year when it bought two old heart drugs — Isuprel and Nitropress — that had little competition. Despite public outcry, Daraprim's price hasn't budged. Today, many health insurance companies won't pay for the drug, and it's too expensive for many hospitals to keep in stock, says Armstrong. As a result, she says, doctors have been forced to turn to cheaper alternatives that have more side effects and less proof that they work. Then there is EpiPen, used to counteract allergic reactions. By the time the EpiPen's list price reached $300 per auto-injector in 2016, its manufacturer, Mylan, had made more than a dozen price hikes in just six years. People clamored for a cheaper generic of the product, which injects a dose of epinephrine to counteract allergic reactions. Mylan had a virtual monopoly on it. In the spring of 2016, the FDA had rejected two applications from other firms that wanted to make generic versions. State and federal lawmakers took notice. For years, they had been passing laws that pushed for schools and other public places to have EpiPens on hand. Mylan started offering its own generic at half the price in December 2016 and left the price of its brand-name product where it was. Mylan's new version is called an authorized generic. These are usually introduced to undercut competition from other companies' generics — and eat into some of the competitors' profits. Next consider Sovaldi: a first-of-its-kind hepatitis C drug, priced at $1,000 per pill. To rid a patient of the hepatitis C virus would cost $84,000 per person. State health systems struggled to pay for the treatment, and health insurers denied the drug to all but the sickest patients. An investigation led by Iowa Republican Sen. Chuck Grassley and Oregon Democratic Sen. Ron Wyden found that state Medicaid programs spent more than $1 billion on the drug in 2014, but less than 2.4% of Medicaid patients with hepatitis C got Sovaldi. Now, there are a few other brand-name hepatitis C cures on the market, creating some competition. Finally: Insulin After insulin was discovered nearly 100 years ago, the rights to it were transferred to the University of Toronto for $1 so that insulin could be made widely available at a low cost. But insulin prices have continued to creep upward at a rate that's higher than inflation. As a result, some patients have rationed their medicine, skipping doses or cutting them in half. In 2017, a group of patients sued the three major insulin-makers — Sanofi, Eli Lilly and Novo Nordisk — when they noticed that the companies were increasing their prices in lockstep. When Congress and the media took notice, the price hikes mostly stopped, but prices didn't drop. In December, the House passed a bill to lower prescription drug prices.

HAPPY NEW YEAR A Decade Marked By Outrage Over Drug Prices Martin Shkreli, the former CEO of Turing Pharmaceuticals, who was called before Cummings' committee in2016. After hiking the price of an old drug for parasitic infections to $750 a pill from $13.50, Shkreli became the poster boy for pharmaceutical greed that helped define the past decade. Meanwhile, nearly 1 in 4 Americans has trouble affording prescription drugs, according to a Kaiser Family Foundation poll. Of relevance, perhaps to our NA members, Daraprim: An old drug gets a huge new price For decades, Daraprim has been the go-to medicine for treating toxoplasmosis, a parasitic infection especially dangerous for people with compromised immune systems, such as people living with HIV and patients who've undergone organ transplants. The drug was approved by the Food and Drug Administration in 1953, and its patents expired long ago. But there wasn't a generic version available, and there was only one supplier in the United States. Even so, Daraprim cost just $13.50 a pill in early 2015. Then Turing Pharmaceuticals bought the rights to the drug and raised its list price more than 5,000% overnight. Another company called Valeant did the same year when it bought two old heart drugs — Isuprel and Nitropress — that had little competition. Despite public outcry, Daraprim's price hasn't budged. Today, many health insurance companies won't pay for the drug, and it's too expensive for many hospitals to keep in stock, says Armstrong. As a result, she says, doctors have been forced to turn to cheaper alternatives that have more side effects and less proof that they work. Then there is EpiPen, used to counteract allergic reactions. By the time the EpiPen's list price reached $300 per auto-injector in 2016, its manufacturer, Mylan, had made more than a dozen price hikes in just six years. People clamored for a cheaper generic of the product, which injects a dose of epinephrine to counteract allergic reactions. Mylan had a virtual monopoly on it. In the spring of 2016, the FDA had rejected two applications from other firms that wanted to make generic versions. State and federal lawmakers took notice. For years, they had been passing laws that pushed for schools and other public places to have EpiPens on hand. Mylan started offering its own generic at half the price in December 2016 and left the price of its brand-name product where it was. Mylan's new version is called an authorized generic. These are usually introduced to undercut competition from other companies' generics — and eat into some of the competitors' profits. Next consider Sovaldi: a first-of-its-kind hepatitis C drug, priced at $1,000 per pill. To rid a patient of the hepatitis C virus would cost $84,000 per person. State health systems struggled to pay for the treatment, and health insurers denied the drug to all but the sickest patients. An investigation led by Iowa Republican Sen. Chuck Grassley and Oregon Democratic Sen. Ron Wyden found that state Medicaid programs spent more than $1 billion on the drug in 2014, but less than 2.4% of Medicaid patients with hepatitis C got Sovaldi. Now, there are a few other brand-name hepatitis C cures on the market, creating some competition. Finally: Insulin After insulin was discovered nearly 100 years ago, the rights to it were transferred to the University of Toronto for $1 so that insulin could be made widely available at a low cost. But insulin prices have continued to creep upward at a rate that's higher than inflation. As a result, some patients have rationed their medicine, skipping doses or cutting them in half. In 2017, a group of patients sued the three major insulin-makers — Sanofi, Eli Lilly and Novo Nordisk — when they noticed that the companies were increasing their prices in lockstep. When Congress and the media took notice, the price hikes mostly stopped, but prices didn't drop. In December, the House passed a bill to lower prescription drug prices.

By  Dylan Scott, Posted with permission from STAT When Martin Shkreli’s Turing Pharmaceuticals hiked the price of its anti-parasitic drug to $750 a pill, there was public outcry. So Turing and… The post How are prescription drug prices determined? appeared first on DrugPatentWatch - Make Better Decisions.

Dr. Ameet Sarpatwari is an epidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. A. Sarpatwari, J. Avorn, and A.S. Kesselheim. State Initiatives to Control Medication Costs — Can Transparency Legislation Help? N Engl J Med 2016;374:2301-4.

Former Turing Pharmaceuticals CEO Martin Schkreli was under the microscope of the govenrment recently due to his poor business practices. But are price controls the answer in the already heavily regulated Pharmaceuticals market? Sincere we are anarchists, you no doubt know our opinion on the matter.Martin Shkreli pleads the Fifth, then tweets about 'imbeciles' in CongressCostly Turing drug gets competitionPharmaceutical offers $1 option to Turing’s $750 AIDS drugDaraprimPharmaceuticals: Economics and RegulationPrice ControlsInterested in learning more about economics, logic, and history? Then sign up for Tom Woods Liberty Classroom.Interested in Bitcoin as an alternative to US Dollars? Use our Coinbase link!If you sign up with our coinbase link and purchase $100 in bitcoin, you will recieve an extra $10 from coinbase.The "Shift" Bitcoin debit card is through coinbase as well.Support the show by entering Amazon through our link HERE!Support the show with Bitcoin HERE!Use this address to add the Logical Anarchy Today show to your podcatcher or subscribe on iTunes!http://shoutengine.com/LogicalAnarchyToday.xml 

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

In the eighth installment of the OFID podcast, Editor Paul Sax, MD, delves into the headline-making pyrimethamine (Daraprim) saga where Turing Pharmaceuticals increased the price of the recently-acquired toxoplasmosis drug from $13 to $750 a pill. Aaron Kesselheim, MD, JD, MPH, and Joel Gallant, MD, MPH, join the discussion to shed light on what is unique about the generic drug market in the U.S. that makes these dramatic price increases possible and if there will be any resolution.

So theres a guy named Martin Shkreli and he owns a company named Turing Pharmaceuticals. They have a drug called Daraprim used for HIV and he proudly announced this week that he raised the price from $13 a pill to $750 a pill like it was a great thing to do!  Well this pill has a serious group of users that have HIV and the world went into a tizzy cause Martin is proving why being a conservative greedy CEO of company is not cool.  Mark and Bobby discuss this.Then Mark and Producer Bobby go down a unique path as Mark talks about how we are just not happy with the Status quo anymore, yet we don't come up with anything more ingenius than the status quo.  They discuss how Lays potato chips are constantly trying to change the game with new weird flavors and there is nothing wrong with normal old Sour cream and Onion, Cheddar, BBQ and regular potato chips. Where do you stand?  Do you like the 900 varieties or were you fine and life worked well with the orignal 5-7 that already existed.  See where this goes on this episode of the Q. 

Today in FirstWord:

Hillary Clinton, the Democratic front runner in the race for the White House, pledged this week to crack down on the growing cost of prescription drugs and out of pocket medical expenses in the United States after Turing Pharmaceuticals announced that it was hiking the price of the drug Daraprim from $13.50 to $750 a pill. Aimee Keane asks David Crow about the sharp falls in biotech stocks that followed and whether plans such as Mrs Clinton's will end price-gouging. Music: "Starday" by Podington Bear. See acast.com/privacy for privacy and opt-out information.

Today in FirstWord: